Ratings Legend Biotech Corporation

Equities

LEGN

US52490G1022

Real-time Estimate Cboe BZX Other stock markets 02:42:00 2024-05-09 pm EDT			5-day change	1st Jan Change
45.7 ^USD	-0.05%		-0.48%	-24.03%

Apr. 23	Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission	MT
Apr. 22	Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Thanks to a sound financial situation, the firm has significant leeway for investment.
Sales forecast by analysts have been recently revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
LEGEND BIOTECH CORPORATION	-24.03%	8.32B	D
VERTEX PHARMACEUTICALS INCORPORATED	+3.00%	108B	B+
REGENERON PHARMACEUTICALS, INC.	+10.35%	105B	B+
ARGENX SE	+1.57%	23.46B	B
BIONTECH SE	-12.45%	21.72B	B+
GENMAB A/S	-7.05%	18.64B	A-
WUXI APPTEC CO., LTD.	-37.64%	17.45B	A-
BEIGENE, LTD.	-6.54%	17.19B	B
NEUROCRINE BIOSCIENCES, INC.	+6.13%	13.99B	C+
SAREPTA THERAPEUTICS, INC.	+37.18%	12.53B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes